fbpx

IMMUNOCELL®
TECHNOLOGY

DEVELOPING THE NEXT GENERATION OF BIOTHERAPEUTICS
Immunocell® technology is the future class of biotherapeutic based on Induced Pluripotent Stem Cells that are derived from a blastocyst either donated or cloned from a skin cell.

 

Pure Medical is building a pipeline of clinically differentiated immunotherapies leveraging the key benefits of Immunocell® technology. Our aim is to extend the benefits of immunotherapies to all patients, including those who do not experience a durable response to current single immune checkpoint inhibitors.

 

The Immunocell® technology is Pure Medical’s proprietary therapeutic platform with its intellectual property covered by several patent families.
KEY BENEFITS
Immunocell® biotherapeutics have a number of essential advantages over other technologies

 

The main advantages of iPSCs over other stem cells are that they may be made from the same tissue as the patient who will get the transplant, preventing immunological rejection, and that they have no ethical problems because the cells are taken from a willing adult without injuring them. These patient-specific cells can be utilised to research diseases in vitro, test medications on a human model without putting anyone in danger, and possibly act as tissue replacements for diseased and damaged cells.

 

Like other stem cells, iPSCs have the ability to proliferate indefinitely in vitro, creating a theoretically unlimited source of cells. Like embryonic stem cells, iPSCs can also differentiate into any cell of the body, regardless of the original tissue from which they are created.

 

Our Scientists have found how to direct the differentiation of pluripotent stem cells into many types of the target tissue, including neural tissue. iPSCs demonstrate that by the introduction of just four genes into somatic cells that normally cannot differentiate at all, cells can be created that can differentiate into every cell type in the body. The early results of iPSC differentiation studies look promising. For example, human fibroblasts have been successfully turned into iPSCs that then are differentiated into insulin-producing cells, a result that holds much potential for the treatment of diabetes. iPSCs have been differentiated into cardiovascular (heart muscle) cells, which actually shows the contractile beating expected of heart tissue.

 

Although there are still various challenges with iPSCs, Immunocell® technology will revolutionise how diseases, conditions, and neurological disorders are studied and treated in biomedical research. Immunocell® technology has the potential to develop excellent models for the central nervous system cells that are harmed in diseases.

 

Stem cell biology is a very hot topic in modern medicine, yet much is still unknown about the mechanisms underlying pluripotency and differentiation. In order for safe, controllable, and efficient cellular reprogramming to be achieved, there must be more knowledge on the regulation of stem cell states and transitions. iPSCs show that specialised cells and tissue can be transformed into other types of cells, proving cells are much more flexible than previously thought. As the study of diseases, conditions and neurological disorders will greatly benefit from this new, unlimited source of neural cells for research and cell therapy, Immunocell® technology will be able to provide new and innovative treatments.

Stem Cell Therapy Mobile Banner

IMMUNOCELL®
TECHNOLOGY

DEVELOPING THE NEXT GENERATION OF BIOTHERAPEUTICS
Immunocell® technology is the future class of biotherapeutic based on Induced Pluripotent Stem Cells that are derived from a blastocyst either donated or cloned from a skin cell.

 

Pure Medical is building a pipeline of clinically differentiated immunotherapies leveraging the key benefits of Immunocell® technology. Our aim is to extend the benefits of immunotherapies to all patients, including those who do not experience a durable response to current single immune checkpoint inhibitors.

 

The Immunocell® technology is Pure Medical’s proprietary therapeutic platform with its intellectual property covered by several patent families.
KEY BENEFITS
Immunocell® biotherapeutics have a number of essential advantages over other technologies

 

The main advantages of iPSCs over other stem cells are that they may be made from the same tissue as the patient who will get the transplant, preventing immunological rejection, and that they have no ethical problems because the cells are taken from a willing adult without injuring them. These patient-specific cells can be utilised to research diseases in vitro, test medications on a human model without putting anyone in danger, and possibly act as tissue replacements for diseased and damaged cells.

 

Like other stem cells, iPSCs have the ability to proliferate indefinitely in vitro, creating a theoretically unlimited source of cells. Like embryonic stem cells, iPSCs can also differentiate into any cell of the body, regardless of the original tissue from which they are created.

 

Our Scientists have found how to direct the differentiation of pluripotent stem cells into many types of the target tissue, including neural tissue. iPSCs demonstrate that by the introduction of just four genes into somatic cells that normally cannot differentiate at all, cells can be created that can differentiate into every cell type in the body. The early results of iPSC differentiation studies look promising. For example, human fibroblasts have been successfully turned into iPSCs that then are differentiated into insulin-producing cells, a result that holds much potential for the treatment of diabetes. iPSCs have been differentiated into cardiovascular (heart muscle) cells, which actually shows the contractile beating expected of heart tissue.

 

Although there are still various challenges with iPSCs, Immunocell® technology will revolutionise how diseases, conditions, and neurological disorders are studied and treated in biomedical research. Immunocell® technology has the potential to develop excellent models for the central nervous system cells that are harmed in diseases.

 

Stem cell biology is a very hot topic in modern medicine, yet much is still unknown about the mechanisms underlying pluripotency and differentiation. In order for safe, controllable, and efficient cellular reprogramming to be achieved, there must be more knowledge on the regulation of stem cell states and transitions. iPSCs show that specialised cells and tissue can be transformed into other types of cells, proving cells are much more flexible than previously thought. As the study of diseases, conditions and neurological disorders will greatly benefit from this new, unlimited source of neural cells for research and cell therapy, Immunocell® technology will be able to provide new and innovative treatments.

Pure Medical Immunocell Mobile Footer